id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-0926-0005,FDA,FDA-2022-E-0926,Determination of Regulatory Review Period for Purposes of Patent Extension; CYTALUX,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2024-06-15T01:00:26Z,2023-28507,0,0,090000648635c493
FDA-2022-E-0926-0004,FDA,FDA-2022-E-0926,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-01T19:50:01Z,,0,0,09000064862d409a